Conjunctival Swab Positivity 12.7 Percent for SARS-CoV-2 Patients

Among hospitalized patients with SARS-CoV-2, eyes with CS positivity had significantly higher conjunctival redness grade

Conjunctival Swab Positivity 12.7 Percent for SARS-CoV-2 Patients
Adobe Stock

MONDAY, April 18, 2022 (HealthDay News) -- For hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity, conjunctival swab (CS) positivity is 12.7 percent, and 45.1 percent have at least one conjunctival manifestation, according to a research letter published online April 19 in JAMA Network Open.

Emilio Pedrotti, M.D., from the University of Verona in Italy, and colleagues examined the prevalence of SARS-CoV-2-related conjunctival manifestations and CS positivity on hospital admission (T1) and three days thereafter (T2) among a sample of 142 patients not receiving anti-inflammatory treatment. All patients received hyaluronic acid artificial tears (ATs) twice daily in the clinically worse eye: nonpreservative-free (NPF) ATs with povidone iodine were administered at one hospital and preservative-free (PF) ATs were administered at two hospitals. Conjunctival redness (CR) and other conjunctival signs and symptoms (OCSSs) were compared between T1 and T2 and between AT-treated and nontreated eyes.

The researchers found that 12.7 percent of the patients had a positive CS result and 45.1 percent had at least one clinical finding (e.g., CR). Eyes with CS positivity had significantly higher CR grade. At T2, 8.5 percent of patients had a positive CS result. Five additional patients were in the non-AT group and 14 fewer in the AT group. Among nontreated eyes, redness worsened, while among AT-treated eyes, both CR and OCSSs improved. NPF-ATs were 1.13 times more effective than PF-ATs for improving CR and were the only formulation able to reduce OCSSs and CS positivity.

"These results suggest a concordance between CR grade and CS positivity," the authors write.

Abstract/Full Text

Physician's Briefing